Key result
This editorial introduces a themed collection on Cardiovascular-Oncology, highlighting the need to understand mechanisms of anti-cancer drug cardiovascular toxicity to develop cardioprotective strategies.
Highlights the importance of understanding mechanistic pathways in cardio-oncology to develop cardioprotective strategies during cancer treatment.
Dramatic improvements in cancer survival have arisen because of the rapid development of novel anti-cancer therapies. The potential for cardiovascular toxicity associated with these drugs often reflects overlap between pathogenic cancer mechanisms and physiological pathways required for normal cardiovascular function. Clinical Science has, therefore, compiled a themed collection on Cardiovascular-Oncology. This collection examines the intersection between cancer treatments and their potentially harmful cardiovascular effects. By defining the mechanisms underlying unwanted cardiovascular effects of anti-cancer therapies, cardioprotective strategies can be developed. Only by doing so, will patients be able to achieve optimal cancer treatment at the minimum cost to cardiovascular health.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2021) conducted an editorial in Cardiovascular toxicity of anti-cancer therapies. Anti-cancer therapies was evaluated. This editorial introduces a themed collection on Cardiovascular-Oncology, highlighting the need to understand mechanisms of anti-cancer drug cardiovascular toxicity to develop cardioprotective strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: